// App-Quantinova.ai

14 : CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered NK Cells and T Cells Enhance In Vitro and In Vivo Anti-Tumor Activity Against Human Multiple Myeloma

Researchers

Presenter

  • Jianhong Chu

Principal Investigators

  • Youcai Deng

  • Don M. Benson Jr

  • Steven M. Devine

  • Xiaoliu Zhang

  • Michael A. Caligiuri

  • Craig C Hofmeister

  • Jianhua Yu

  • Shun He

  • Tiffany L Hughes

  • Jianying Zhang

  • Yong Peng

  • Hsiaoyin Mao

  • Ling Yi

  • Kalpana Ghoshal

  • Xiaoming He

Medical Centers

  • Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Department of Pathology, The Ohio State University, Columbus, OH

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Center for Biostatistics, The Ohio State University, Columbus, OH

  • The Ohio State Univerisity, Columbus, OH

  • Hematology, The Ohio State University-James Cancer Center, Columbus, OH

  • Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Acute lymphoblastic leukemia

  • B cell lymphomas

  • Multiple Myeloma

Biomarkers

  • Natural Killer cells

  • Breakpoint Cluster Region

  • Cluster of Differentiation 2AP

  • Interleukin-2

Drug/Treatment

  • Elotuzumab

  • IFN-lambda

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved